Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 326

1.

Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.

Fogli S, Porta C, Del Re M, Crucitta S, Gianfilippo G, Danesi R, Rini BI, Schmidinger M.

Cancer Treat Rev. 2020 Mar;84:101966. doi: 10.1016/j.ctrv.2020.101966. Epub 2020 Jan 17. Review.

PMID:
32044644
2.

Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer - Combination Therapy in the First Line Setting.

Aggen DH, Drake CG, Rini BI.

Clin Cancer Res. 2020 Jan 16. pii: clincanres.3323.2019. doi: 10.1158/1078-0432.CCR-19-3323. [Epub ahead of print]

PMID:
31948999
3.

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).

Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ, Pal SK, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB.

J Immunother Cancer. 2019 Dec 20;7(1):354. doi: 10.1186/s40425-019-0813-8.

4.

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.

Rini BI, Pal SK, Escudier BJ, Atkins MB, Hutson TE, Porta C, Verzoni E, Needle MN, McDermott DF.

Lancet Oncol. 2020 Jan;21(1):95-104. doi: 10.1016/S1470-2045(19)30735-1. Epub 2019 Dec 3.

PMID:
31810797
5.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.

Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15.

6.

Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.

Escudier B, Motzer RJ, Tannir NM, Porta C, Tomita Y, Maurer MA, McHenry MB, Rini BI.

Eur Urol. 2019 Nov 13. pii: S0302-2838(19)30824-3. doi: 10.1016/j.eururo.2019.10.025. [Epub ahead of print]

PMID:
31732098
7.

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.

Courtney KD, Ma Y, Diaz de Leon A, Christie A, Xie Z, Woolford L, Singla N, Joyce A, Hill H, Madhuranthakam AJ, Yuan Q, Xi Y, Zhang Y, Chang J, Fatunde O, Arriaga Y, Frankel AE, Kalva S, Zhang S, McKenzie T, Reig Torras O, Figlin RA, Rini BI, McKay RM, Kapur P, Wang T, Pedrosa I, Brugarolas J.

Clin Cancer Res. 2020 Feb 15;26(4):793-803. doi: 10.1158/1078-0432.CCR-19-1459. Epub 2019 Nov 14.

PMID:
31727677
8.

Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs.

Tannenbaum CS, Rayman PA, Pavicic PG, Kim JS, Wei W, Polefko A, Wallace W, Rini BI, Morris-Stiff G, Allende DS, Hamilton T, Finke JH, Diaz-Montero CM.

Cancer Immunol Res. 2019 Oct;7(10):1687-1699. doi: 10.1158/2326-6066.CIR-18-0578. Epub 2019 Aug 22.

PMID:
31439615
9.

Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.

Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, Rathmell WK, Garcia JA, Rini BI.

Lancet Oncol. 2019 Oct;20(10):1386-1394. doi: 10.1016/S1470-2045(19)30513-3. Epub 2019 Aug 16.

PMID:
31427205
10.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators.

Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Erratum in: Lancet Oncol. 2019 Aug 21;:.

PMID:
31427204
11.

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.

de Velasco G, Bex A, Albiges L, Powles T, Rini BI, Motzer RJ, Heng DYC, Escudier B.

Eur Urol Oncol. 2019 Sep;2(5):505-514. doi: 10.1016/j.euo.2019.06.022. Epub 2019 Aug 1. Review.

PMID:
31377308
12.

Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply.

Rini BI, Powles T.

N Engl J Med. 2019 Jun 27;380(26):2582. doi: 10.1056/NEJMc1905518. No abstract available.

PMID:
31242371
13.

Adjuvant therapy in renal cell carcinoma.

Gul A, Rini BI.

Cancer. 2019 Sep 1;125(17):2935-2944. doi: 10.1002/cncr.32144. Epub 2019 Jun 21. Review.

PMID:
31225907
14.

Immunotherapy for renal cell carcinoma.

Sheng IY, Rini BI.

Expert Opin Biol Ther. 2019 Sep;19(9):897-905. doi: 10.1080/14712598.2019.1628946. Epub 2019 Jun 12.

PMID:
31173514
15.

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.

Ornstein MC, Wood LS, Hobbs BP, Allman KD, Martin A, Bevan M, Gilligan TD, Garcia JA, Rini BI.

J Immunother Cancer. 2019 May 16;7(1):127. doi: 10.1186/s40425-019-0615-z.

16.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group.

Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.

PMID:
31079938
17.

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.

Voss MH, Bhatt RS, Vogelzang NJ, Fishman M, Alter RS, Rini BI, Beck JT, Joshi M, Hauke R, Atkins MB, Burgess E, Logan TF, Shaffer D, Parikh R, Moazzam N, Zhang X, Glasser C, Sherman ML, Plimack ER.

Cancer. 2019 Jul 15;125(14):2400-2408. doi: 10.1002/cncr.32061. Epub 2019 Apr 5.

PMID:
30951193
18.

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2019 Mar 14;7(1):73. doi: 10.1186/s40425-019-0559-3.

19.

Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.

Ornstein MC, Calabrese C, Wood LS, Kirchner E, Profusek P, Allman KD, Martin A, Kontzias A, Grivas P, Garcia JA, Calabrese LH, Rini BI.

Clin Genitourin Cancer. 2019 Jun;17(3):177-182. doi: 10.1016/j.clgc.2019.01.021. Epub 2019 Feb 7.

PMID:
30824360
20.

Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis.

Field CA, Cotta BH, Jimenez J, Lane BR, Yim K, Lee HJ, Ryan ST, Hamilton ZA, Patel S, Wang S, Kane CJ, Dey S, Mckay RR, Noyes S, Millard FE, Rini BI, Campbell SC, Derweesh IH.

Clin Genitourin Cancer. 2019 Jun;17(3):e505-e512. doi: 10.1016/j.clgc.2019.01.013. Epub 2019 Jan 30.

PMID:
30808547
21.

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators.

N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.

PMID:
30779529
22.

HIF Inhibitors: Status of Current Clinical Development.

Fallah J, Rini BI.

Curr Oncol Rep. 2019 Jan 22;21(1):6. doi: 10.1007/s11912-019-0752-z. Review.

PMID:
30671662
23.

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.

Cella D, Grünwald V, Escudier B, Hammers HJ, George S, Nathan P, Grimm MO, Rini BI, Doan J, Ivanescu C, Paty J, Mekan S, Motzer RJ.

Lancet Oncol. 2019 Feb;20(2):297-310. doi: 10.1016/S1470-2045(18)30778-2. Epub 2019 Jan 15. Erratum in: Lancet Oncol. 2019 Jun;20(6):e293.

24.

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study.

Tomita Y, Uemura H, Oya M, Shinohara N, Habuchi T, Fujii Y, Kamei Y, Umeyama Y, Bair AH, Rini BI.

BMC Cancer. 2019 Jan 7;19(1):17. doi: 10.1186/s12885-018-5224-6.

25.

Radical shifts in the first-line management of metastatic renal cell carcinoma.

Ornstein MC, Rini BI.

Nat Rev Clin Oncol. 2019 Feb;16(2):71-72. doi: 10.1038/s41571-018-0146-4. No abstract available.

PMID:
30538304
26.

Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.

Cella D, Motzer RJ, Rini BI, Cappelleri JC, Ramaswamy K, Hariharan S, Arondekar B, Bushmakin AG.

Value Health. 2018 Dec;21(12):1413-1418. doi: 10.1016/j.jval.2018.04.1371. Epub 2018 May 11.

27.

Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A Review.

George S, Rini BI, Hammers HJ.

JAMA Oncol. 2019 Mar 1;5(3):411-421. doi: 10.1001/jamaoncol.2018.4604. Review.

PMID:
30476955
28.

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2018 Oct 22;6(1):109. doi: 10.1186/s40425-018-0420-0. Erratum in: J Immunother Cancer. 2019 Mar 14;7(1):73.

29.

Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies.

Kroeger N, Li H, De Velasco G, Donskov F, Sim HW, Stühler V, Wells JC, Stukalin I, Heide J, Bedke J, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK, Chin Heng DY.

Clin Genitourin Cancer. 2019 Feb;17(1):65-71. doi: 10.1016/j.clgc.2018.09.006. Epub 2018 Sep 12.

PMID:
30341028
30.

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.

Zahoor H, Barata PC, Jia X, Martin A, Allman KD, Wood LS, Gilligan TD, Grivas P, Ornstein MC, Garcia JA, Rini BI.

J Immunother Cancer. 2018 Oct 17;6(1):107. doi: 10.1186/s40425-018-0425-8.

31.

Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.

Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P.

Clin Cancer Res. 2019 Jan 1;25(1):210-221. doi: 10.1158/1078-0432.CCR-18-1278. Epub 2018 Oct 16.

32.

Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T, Basappa NS, Kanesvaran R, Wood LA, Canil C, Kapoor A, Fu SYF, Choueiri TK, Heng DYC.

Cancer. 2018 Sep 15;124(18):3677-3683. doi: 10.1002/cncr.31595. Epub 2018 Oct 11.

33.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0235-z.

PMID:
30291359
34.

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.

Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG Jr, Finke JH, Barata PC, Lamenza M, Devonshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, Garcia JA, Gilligan TD, Ornstein MC, Grivas P.

Target Oncol. 2018 Oct;13(5):599-609. doi: 10.1007/s11523-018-0595-9.

PMID:
30267200
35.

Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery.

Almassi N, Gao T, Lee B, Stein RJ, Haber GP, Ornstein MC, Rini BI, Gilligan TD, Garcia JA, Stephenson AJ, Grivas P.

Clin Genitourin Cancer. 2018 Dec;16(6):e1237-e1242. doi: 10.1016/j.clgc.2018.08.003. Epub 2018 Aug 22.

PMID:
30217764
36.

Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma.

Zahoor H, Pavicic PG Jr, Przybycin C, Ko J, Stephens L, Radivoyevitch T, Jia X, Diaz-Montero CM, Finke J, Rayman PA, Gilligan TD, Grivas P, Ornstein M, Garcia JA, Rini BI.

Medicine (Baltimore). 2018 Sep;97(37):e12344. doi: 10.1097/MD.0000000000012344.

37.

Information Transparency in the Drug Approval Process.

Rini BI, Burstein HJ, George DJ.

JAMA Oncol. 2018 Nov 1;4(11):1621-1622. doi: 10.1001/jamaoncol.2018.4143. No abstract available.

PMID:
30193367
38.

Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma.

Barata PC, Mendiratta P, Kotecha R, Gopalakrishnan D, Juloori A, Chao ST, Koshkin V, Ornstein M, Gilligan TD, Wood LS, Rini BI, Angelov L, Garcia JA.

Clin Genitourin Cancer. 2018 Oct;16(5):413-419.e1. doi: 10.1016/j.clgc.2018.07.018. Epub 2018 Aug 17.

PMID:
30172552
39.

The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.

Chen YW, Ornstein MC, Wood LS, Allman KD, Martin A, Beach J, Gilligan T, Garcia JA, Rini BI.

Urol Oncol. 2018 Oct;36(10):470.e19-470.e29. doi: 10.1016/j.urolonc.2018.06.013. Epub 2018 Aug 18.

PMID:
30131292
40.

Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.

Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA.

Prostate. 2018 Sep;78(13):1035-1041. doi: 10.1002/pros.23663. Epub 2018 Jun 7.

PMID:
29882332
41.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4. Erratum in: Nat Med. 2018 Dec;24(12):1941.

42.

Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.

Rini BI, Hutson TE, Figlin RA, Lechuga MJ, Valota O, Serfass L, Rosbrook B, Motzer RJ.

Clin Genitourin Cancer. 2018 Aug;16(4):298-304. doi: 10.1016/j.clgc.2018.04.005. Epub 2018 May 4.

43.

The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma.

Barata PC, De Liano AG, Mendiratta P, Crolley V, Szabados B, Morrison L, Wood L, Allman K, Tyler A, Martin A, Gilligan T, Grivas P, Ornstein M, Garcia JA, Powles T, Rini BI.

Br J Cancer. 2018 Jul;119(2):160-163. doi: 10.1038/s41416-018-0104-z. Epub 2018 May 24.

44.

Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.

Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A.

Clin Cancer Res. 2018 Sep 15;24(18):4407-4415. doi: 10.1158/1078-0432.CCR-18-0323. Epub 2018 May 17.

45.

Current and emerging first-line systemic therapies in clear cell renal cell carcinoma.

Rini BI.

Clin Adv Hematol Oncol. 2018 Feb;16(2):115-117. No abstract available.

PMID:
29741511
46.

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.

Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI.

J Clin Oncol. 2018 Jun 1;36(16):1588-1593. doi: 10.1200/JCO.2017.77.1485. Epub 2018 Apr 11.

47.

Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies.

Barata PC, Gopalakrishnan D, Koshkin VS, Mendiratta P, Karafa M, Allman K, Martin A, Beach J, Profusek P, Tyler A, Wood L, Ornstein M, Gilligan T, Rini BI, Garcia JA, Grivas P.

Target Oncol. 2018 Jun;13(3):353-361. doi: 10.1007/s11523-018-0561-6.

PMID:
29623487
48.

Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.

Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, Rini BI, Garcia JA, Grivas P.

Urol Oncol. 2018 Sep;36(9):405-412. doi: 10.1016/j.urolonc.2018.02.018. Epub 2018 Mar 30. Review.

PMID:
29606341
49.

Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more.

Zahoor H, Rini BI, Ornstein MC.

Oncotarget. 2017 Dec 6;9(18):14036-14037. doi: 10.18632/oncotarget.23005. eCollection 2018 Mar 6. No abstract available.

50.

Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.

Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, Fergany AF, Kaouk J, Haber GP, Stephenson AJ, Ornstein MC, Gilligan T, Garcia JA, Rini BI, Grivas P.

Clin Genitourin Cancer. 2018 Aug;16(4):e879-e892. doi: 10.1016/j.clgc.2018.02.002. Epub 2018 Feb 22.

PMID:
29576445

Supplemental Content

Loading ...
Support Center